Peptide purity testing is the set of analytical procedures a laboratory uses to answer two distinct questions about a research compound: is this the molecule it claims to be, and how much of the sample is something other than that molecule? In practice these questions are answered by two complementary instruments, high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Understanding what each one measures, and what it cannot measure, is the difference between reading a certificate of analysis critically and taking a number on faith.
Identity Versus Purity: Two Separate Measurements
It is tempting to treat “purity” as a single percentage, but analytically the concepts of identity and purity are decoupled. Identity asks whether the sequence and mass correspond to the intended structure. Purity asks what fraction of the material is the target compound rather than synthesis by-products, truncated sequences, deletion or insertion variants, or residual solvents and counter-ions. A sample can have the correct identity and still be substantially impure, and a high purity figure means little if the identity has not been independently confirmed. Rigorous quality control therefore pairs a separation technique that quantifies components with a detection technique that identifies them, which is why HPLC and MS are almost always reported together in the peer-reviewed literature.
How HPLC Measures Peptide Purity
Reversed-phase HPLC (RP-HPLC) is the workhorse of peptide purity testing. A small volume of dissolved peptide is pushed through a column packed with a hydrophobic stationary phase, typically a C18 material, while the mobile phase gradually shifts from aqueous to organic. Components elute at different times according to how strongly they interact with the column, and a detector, usually ultraviolet absorbance at 214 nm where the peptide bond absorbs, records each as a peak. Purity is then estimated as the area of the main peak divided by the total area of all peaks.
The apparent simplicity hides real method-dependence. Work on cationic cell-penetrating peptides has shown that column particle size, the acidic modifier in the mobile phase (formic acid versus trifluoroacetic acid), and column temperature all measurably change resolution and the resulting purity figure, so a single set of chromatographic conditions is not universally optimal (Stalmans et al., 2015). Chiral impurities add a further layer: a D-amino acid substitution produces a molecule of identical mass that a standard achiral column may not resolve at all, which is why dedicated enantioselective methods have been developed to separate stereoisomers that would otherwise hide inside the main peak (Pucciarini et al., 2019). A purity value is only ever as good as the method’s ability to pull impurities away from the main peak.
What Mass Spectrometry Adds
Mass spectrometry supplies the identity dimension that a UV trace alone cannot. By ionizing the molecule and measuring its mass-to-charge ratio, MS confirms whether the observed mass matches the theoretical mass of the intended sequence, and tandem MS can fragment the peptide to read sequence-level detail. When an MS detector is coupled downstream of the HPLC, each chromatographic peak can be assigned a mass, so an analyst can identify not just the target but also the impurities eluting around it, and can assess whether a peak is spectrally pure (Stalmans et al., 2015). This coupling is what turns a purity percentage into a characterized profile rather than an anonymous one.
MS also underpins the most exacting form of quantification. Isotope-dilution mass spectrometry, in which a stable-isotope-labeled version of the peptide is spiked in as an internal standard, has been used to assign certified reference values traceable to international measurement standards, for example in the development of an insulin-like growth factor-1 reference material (Liu et al., 2024). The same principle, an isotopically labeled internal standard, allows selective quantification of a target peptide even in complex biological matrices (Bronsema et al., 2018).
The Coelution Problem and Orthogonal Methods
The central limitation of any single separation is coelution: two different species arriving at the detector at the same time appear as one peak and inflate the apparent purity. Mass spectrometry does not fully rescue the situation, because isomers and diastereomers share the same mass-to-charge ratio and cannot be told apart by mass alone; they must be separated chromatographically first. To confront this, analysts turn to orthogonal separations. Two-dimensional liquid chromatography coupled to MS uses a first dimension to survey a broad range of impurities and a second, differently selective dimension to interrogate species that might hide under the target peak, a strategy developed specifically to verify main-peak purity for pharmaceutical peptides (Petersson et al., 2023; Stoll et al., 2023). The broader lesson for interpreting any purity claim is that a percentage from one method is a lower bound on impurity, not a guarantee of homogeneity.
Reading Peptide Purity Testing Results Critically
For a researcher evaluating documentation, a few habits follow directly from the science. Confirm that identity (a mass spectrum) and purity (a chromatogram with an integrated main-peak percentage) are both present, since one without the other is incomplete. Note the chromatographic conditions, because purity is method-dependent and an under-resolving method reports flattering numbers. Recognize that standard achiral HPLC may not detect stereoisomeric impurities. Independent analyses of commercial peptide preparations have documented real variability in both purity and absolute content between products (Bronsema et al., 2018), which is precisely why the analytical methods above exist and why the certificate, not the label, is the object worth scrutinizing.
References
- Stalmans S, Gevaert B, Verbeke F, et al. Quality control of cationic cell-penetrating peptides. J Pharm Biomed Anal. 2015;117:289-97. https://doi.org/10.1016/j.jpba.2015.09.011
- Petersson P, Buckenmaier S, Euerby MR, Stoll DR. A strategy for assessing peak purity of pharmaceutical peptides using 2D-LC-MS. Part I: Selection of columns and mobile phases. J Chromatogr A. 2023;1693:463874. https://doi.org/10.1016/j.chroma.2023.463874
- Stoll DR, Sylvester M, Euerby MR, Buckenmaier SMC, Petersson P. A strategy for assessing peak purity of pharmaceutical peptides using 2D-LC-MS. Part II: Development of second-dimension gradient conditions. J Chromatogr A. 2023;1693:463873. https://doi.org/10.1016/j.chroma.2023.463873
- Liu Z, Zhao X, Liu Y, et al. Development of an insulin-like growth factor-1 certified reference material by SI-traceable isotope-dilution mass spectrometry. Talanta. 2024;273:125812. https://doi.org/10.1016/j.talanta.2024.125812
- Bronsema KJ, Klont F, Schalk FB, Bischoff R, Kema IP, van de Merbel NC. A quantitative LC-MS/MS method for insulin-like growth factor 1 in human plasma. Clin Chem Lab Med. 2018;56(11):1905-1912. https://doi.org/10.1515/cclm-2017-1042
- Pucciarini L, Gilardoni E, Ianni F, et al. Development and validation of a HPLC method for the direct separation of carnosine enantiomers and analogues in dietary supplements. J Chromatogr B. 2019;1126-1127:121747. https://doi.org/10.1016/j.jchromb.2019.121747
Research Use Only. The compounds and analytical methods discussed here are described strictly for laboratory and scientific-research purposes. Nothing in this article is intended for human or animal consumption, nor as medical, diagnostic, or therapeutic guidance. Sources are cited via PubMed; DOI links point to the original peer-reviewed publications.